Sevasemten Dose 3

DRUG2 trials

Sponsors

Edgewise Therapeutics, Inc.

Conditions

Duchenne Muscular Dystrophy

Phase 2

A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)

Active, not recruitingNCT05540860

Edgewise Therapeutics, Inc.Duchenne Muscular Dystrophy

Start: 2022-10-24End: 2027-01-31Updated: 2025-11-12

Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy

Active, not recruitingNCT06100887

Edgewise Therapeutics, Inc.Duchenne Muscular Dystrophy

Start: 2024-03-22End: 2027-03-31Updated: 2025-11-06

Related Papers

A Phase 1, Double‐Blind, Placebo‐Controlled Trial of Sevasemten (<scp>EDG</scp>‐5506), a Selective Modulator of Fast Skeletal Muscle Contraction, in Healthy Volunteers and Adults With Becker Muscular Dystrophy

Muscle & Nerve2025-06-021 citations